Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST: Pembrolizumab and SBRT in Advanced Urothelial Carcinoma
NCT03287050Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in urothelial carcinoma (UC), sponsored by University of Michigan Rogel Cancer Center. Started Jan 2018; status: terminated.
02
Drugs
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03287050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287050.